Table 2 Comparison of TNM staging for 18F-FDG PET/CT, 18F-FDG PET/MRI and tumour board consensus. Participant 13 had no increased tumour FDG uptake compared to background
From: Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI
Participant | 18F-FDG PET/CT | 18F-FDG PET/MRI | Tumour board consensus | ||||||
|---|---|---|---|---|---|---|---|---|---|
T | N | M | T | N | M | T | N | M | |
1 | 3 | 3 | 1 | 3 | 3 | 1 | 3 | 2 | 1 |
2 | 3 | 1 | 1 | 4 | 1 | 1 | 3 | 1 | 0 |
3 | 2 | 2 | 1 | 2 | 1 | 1 | 3 | 2 | 1 |
4 | 2 | 2 | 0 | 3 | 2 | 0 | 3 | 2 | 0 |
5 | 2 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 0 |
6 | 2 | 2 | 0 | 4 | 1 | 0 | 3 | 1 | 0 |
7 | 2 | 1 | 0 | 3 | 1 | 0 | 4 | 1 | 0 |
8 | 3 | 1 | 0 | 3 | 1 | 0 | 3 | 1 | 0 |
9 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0 |
10 | 3 | 2 | 0 | 3 | 2 | 0 | 3 | 1 | 0 |
11 | 2 | 3 | 1 | 3 | 3 | 1 | 3 | 2 | 1 |
12 | 3 | 1 | 0 | 3 | 1 | 0 | 3 | 2 | 0 |
13 | 3 | 1 | 0 | 3 | 1 | 0 | 3 | 1 | 0 |
14 | 2 | 1 | 0 | 4 | 2 | 0 | 3 | 1 | 0 |
15 | 3 | 3 | 0 | 3 | 3 | 0 | 4 | 2 | 0 |
16 | 3 | 2 | 1 | 3 | 3 | 1 | 3 | 1 | 1 |
17 | 2 | 3 | 1 | 2 | 3 | 1 | 3 | 3 | 1 |
18 | 2 | 2 | 1 | 3 | 1 | 1 | 3 | 3 | 1 |
19 | 2 | 1 | 1 | 2 | 1 | 1 | 3 | 2 | 1 |
20 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 1 | 0 |
21 | 3 | 2 | 1 | 4 | 2 | 1 | 4 | 3 | 1 |
22 | 4 | 2 | 1 | 4 | 2 | 1 | 4 | 2 | 1 |